KRAS and familial pancreatic carcinoma: Given the heterogeneity of these results, we sought to assess the correlation between the KRAS G12D mutation subtype and survival in pancreatic cancer patients across all clinical stages using tissue biopsies obtained predominantly via EUS-FNA.